Introduction: The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the conversion of the hormonally inactive cortisone to active cortisol, thus facilitating glucocorticoid receptor activation in target tissues. Increased expression of 11β-HSD1 in adipose tissue has been associated with obesity and insulin resistance. In this study, we investigated the association of two 11β-HSD1 gene (HSD11B1) polymorphisms with the metabolic syndrome (MetS) and its characteristics in the Bosnian population.
Introduction
The metabolic syndrome (MetS) represents a cluster of metabolic disorders including abdominal obesity, dyslipidemia (elevated triglycerides and lowered high-density lipoprotein cholesterol (HDLcholesterol)), hyperglycemia and hypertension (1) . These metabolic abnormalities are associated with increased risk for cardiovascular disease and type 2 diabetes mellitus (2, 3) . It is estimated that about 20-30% of the world's adult population has MetS (3). Diagnostic criteria for MetS have changed during the last decade with new insights into the pathogenesis of disease. Diff erent health organi- Dujic T. et al. HSD11B1 polymorphisms and metabolic syndrome zations had proposed their own criteria and fi nally in 2009, a new harmonized defi nition was accepted (1) . MetS is diagnosed when any three of the following fi ve criteria are met: increased waist circumference (with population-and country-specific cut points), triglycerides of at least 150 mg/dL (≥ 1.7 mmol/L), HDL-cholesterol less than 40 mg/dL (< 1.0 mmol/L) in males and less than 50 mg/dL (< 1.3 mmol/L) in females, blood pressure of at least 130/85 mmHg and fasting glucose of at least 100 mg/dL (≥ 5.6 mmol/L) (1) . Recommended waist circumference thresholds for Europids are ≥ 94 cm for men and ≥ 80 cm for women (1) . Abdominal obesity and physical inactivity are considered as major causes for MetS. Beside this, genetic factors, aging and endocrine disorders, all contribute to the susceptibility for disease (2) .
The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) catalyzes the conversion of the hormonally inactive cortisone to active cortisol, thus facilitating glucocorticoid receptor activation in target tissues. It is a microsomal, nicotinamide adenine dinucleotide-dependent dehydrogenase, identifi ed in many tissues, with highest levels of expression in the liver, gonads, adipose tissue, and brain (4) . The similarities between Cushing's syndrome and MetS lead to the hypothesis that increased cortisol concentrations in adipose tissue are implicated in the pathogenesis of visceral obesity and MetS. A transgenic mouse overexpressing 11β-HSD1 in adipose tissue, became a model for MetS with increased visceral fat mass, glucose intolerance, insulin resistance, dyslipidemia and hypertension (5) . In contrast, 11β-HSD1 knockout mice, showed improved insulin sensitivity and lipid profi le (6) . Various studies (7-16), although not all (17) , have reported increased 11β-HSD1 expression in subcutaneous adipose tissue in obese subjects. Some of them confi rmed this association also in visceral adipose depots (7, 11, 16) , while others did not (9, 18, 19) . Several researches found positive correlations of 11β-HSD1 subcutaneous fat expression with markers of insulin resistance (10, 12, 14, 15, 18, 19) . Investigations in animal models and early results of human studies suggest that inhibitors of 11β-HSD1 are promising therapeutic drugs for obesity and diabetes (20) , further supporting the role of 11β-HSD1 in the pathogenesis of MetS (21) .
The gene encoding 11β-HSD1 (HSD11B1) is located on chromosome 1q32-q41. Several studies investigated associations of single-nucleotide polymorphisms (SNPs) of HSD11B1 with metabolic phenotype. Two SNPs within HSD11B1 gene (rs846910: G>A and rs12086634: G>T) have been associated with type 2 diabetes in Pima Indians (15) . SNP rs846910: G>A was also associated with hypertension (22) . Another polymorphism, insertion of adenine in intron 3 (rs45487298: insA), was associated with obesity and insulin resistance in children (23 
Materials and methods

Subjects
The study included a total of 86 participants from Bosnia (27) .
Genetic analyses
Genomic DNA was isolated from peripheral blood using Miller's protocol (28) . Two HSD11B1 gene polymorphisms, rs846910: G>A and rs45487298: insA, were genotyped by previously described high-resolution melting (HRM) method (29) . HRM analysis was performed on the LightCycler ® 480 Real-Time PCR System (Roche Diagnostics GmbH, Mannheim, Germany). Briefl y, DNA fragments containing the analyzed polymorphisms were amplifi ed using the following primers and probes During each run, two positive control samples for each genotype and one negative control were used for quality control. Positive controls were previously confi rmed by PCR-RFLP method (29) . Twenty percent of all samples were double-genotyped with 100% concordant results.
Statistical analysis
Statistical analysis was performed using SPSS Statistics 17.0 software. A P value ≤ 0.05 was considered statistically signifi cant. The diff erences in genotype frequencies between study groups were analyzed by chi-square (χ 2 ) test and Fisher's exact test (in the case where expected frequencies were less or equal to 5). Genotype association with clinical and biochemical markers was tested by MannWhitney test (data did not follow normal distribution). Linkage disequilibrium between two polymorphisms was calculated by 2LD program (30).
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Haplotype analyses were performed using PHASE 2.1 software (31).
Power analysis was performed using the Quanto program version 1.2.4 (32) and G*Power 3 software available at http://www.psycho.uni-duesseldorf. de/abteilungen/aap/gpower3.
Results
Clinical and biochemical variables of MetS patients and controls are presented in Table 1 . Most of the measured anthropometric, hemodynamic and metabolic parameters were signifi cantly diff erent between the two groups except for total and LDLcholesterol concentration (Table 1 ).
Allele and genotype frequencies for rs846910: G>A and rs45487298: insA variants are presented in Table 2. As the rs846910: G>A polymorphism is rare, there were no homozygous mutant genotypes (A/A). There was no signifi cant deviation from the Hardy-Weinberg equilibrium in two groups of subjects studied, with respect to both polymorphisms Distribution of genotypes did not diff er significantly between controls and MetS patients (Table  2) . However, the study had limited power to detect potentially small eff ects of these variants on MetS, which is multifactorial and very complex disease. The power of the study to detect odds ratios (ORs) between 1.2 and 2.0 at α = 0.05 was only 6-24% for rs846910: G>A (dominant model), and 7-33% for rs45487298: insA variant (recessive model). To detect eff ect sizes of OR = 1.2-2.0, sample sizes of nearly 200-3200 and 150-2000 subjects in each group would be required, for rs846910: G>A and rs45487298: insA polymorphism, respectively.
Clinical and metabolic characteristics of patients with MetS according to the genotypes of rs846910: G>A and rs45487298: insA polymorphisms are shown in Table 3 . No signifi cant associations between disease-associated traits and rs45487298: insA were found. Regarding rs846910: G>A variant, heterozygous patients (G/A) had signifi cantly lower systolic (P = 0.017) and diastolic blood pressure (P = 0.015), lower HOMA-IR index (P = 0.011) and 
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higher LDL-cholesterol levels (P = 0.049), compared to the wild-type homozygotes.
Comparisons of clinical and metabolic parameters between genotypes in the control group are shown in Table 4 . The carriers of rs45487298: insA polymorphism had signifi cantly lower fasting plasma insulin (P = 0.041), lower HOMA-IR index (P = 0.041), and lower diastolic blood pressure (P = 0.048), compared to the wild-type homozygotes ( Table 4) . Signifi cant diff erences between rs846910: G>A genotypes in control subjects were not detected (Table 4 ).
In addition, the haplotype analysis was also performed. For continuous traits, the study had only 25% and 34% power to detect moderate eff ect sizes of 0.5 at the α level 0.05, for rs846910: G>A and rs45487298: insA variants, respectively. Sample sizes of 200 and 140 subjects would be needed to detect eff ect sizes of 0.5 with 80% power, for rs846910: G>A and rs45487298: insA polymorphism, respectively. Values represent medians (lower-upper quartile). BMI -body mass index; BP -blood pressure; HOMA-IR -homeostasis model assessment insulin resistance index; LDL -low-density lipoprotein; HDL -high-density lipoprotein; hsCRP -high-sensitivity C-reactive protein. All diff erences were tested using Mann-Whitney test.
TABLE 4.
Comparison of clinical and biochemical characteristics between diff erent genotypes of rs846910: G>A and rs45487298: insA polymorphisms in the control group.
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Discussion
A number of studies have investigated an association of 11β-HSD1 with obesity and insulin resistance in humans. Most of them demonstrated a correlation of adipose HSD11B1 expression with obesity (7-16). Lindsay et al. (14) reported a positive correlation of 11β-HSD1 activity with measures of adiposity, fasting plasma glucose, insulin, and insulin resistance by the homeostasis model. Another study did not fi nd relationship between 11β-HSD1 and insulin sensitivity (33) . The role of 11β-HSD1 in the pathogenesis of visceral obesity and insulin resistance has been corroborated by experimental studies with enzyme inhibitors. However, several studies which explored the relationship between HSD11B1 polymorphisms, obesity and type 2 diabetes, gave confl icting results.
In this study, we did not fi nd the association of two investigated HSD11B1 gene polymorphisms, rs846910: G>A in 5' upstream region and rs45487298: insA in intron 3, with MetS in a sample of Bosnian population. However, our study was preliminary and of limited statistical power due to the insuffi cient sample size. Our negative fi ndings possibly refl ect statistical type 2 errors and the role of investigated genetic variants in MetS risk cannot be ruled out. Analysis of anthropometric and biochemical markers in regards to the genotypes of rs846910: G>A showed signifi cant associations of the mutated A allele with lower systolic (P = 0.017) and diastolic blood pressure (P = 0.015), lower HOMA-IR index (P = 0.011) and higher LDL-cholesterol levels (P = 0.049) in patients with MetS. These results might refl ect the infl uence of rs846910: G>A variant on metabolic control in MetS patients. However, majority of patients in our cohort received therapy and therefore, these associations have to be taken with particular caution.
In the control group, rs846910: G>A did not show any signifi cant associations. Since this allele was rare, we could not confi rm these results by haplotype analysis . Only a few studies have examined the eff ect of rs846910: G>A on the metabolic phenotypes. In a study of Pima Indians, mutated A allele was associated with type 2 diabetes and higher fasting insulin concentrations in healthy subjects, independently of obesity (15) . In another study, also in Pima Indians, rs846910: G>A was associated with hypertension, although these eff ects were modifi ed by birth era of subjects (22) . However, in a recent study, no eff ect of rs846910: G>A variation on HSD11B1 promoter activity in vitro was found (34) , suggesting that this polymorphism may not have direct functional consequences on the 11β-HSD1 activity in vivo.
Analysis of rs45487298: insA polymorphism, showed a signifi cant association between the variant allele and lower fasting plasma insulin levels (P = 0.041), lower HOMA-IR index (P = 0.041), and lower diastolic blood pressure (P = 0.048), in the control group. In MetS patients group, no signifi cant associations were observed. Haplotype analysis confi rmed benefi cial eff ect of rs45487298: insA on markers of insulin resistance in controls with even higher signifi cance (P = 0.011 for fasting plasma insulin and P = 0.016 for HOMA-IR). This polymorphism, as well as another SNP in intron 3, located (35) . These two mutations are in 100% linkage disequilibrium. Interestingly, in the above mentioned study of Pima Indians, the wild-type allele of rs12086634: T>G was associated with type 2 diabetes (15) . It was also associated with higher insulinmediated glucose disposal rate (15) . The authors suggest that the mechanism of association with markers of insulin resistance, independently of obesity, could be modulation of 11β-HSD1 expression in pancreatic beta cells, that is, a tissue-specific regulation of HSD11B1 (15) . On the contrary, in a study sample of healthy overweight and normal weight children from diff erent racial backgrounds, mutated homozygotes for rs45487298: insA had greater BMI, waist circumference and insulin resistance indices than heterozygote or wild-type children (23) . Although no signifi cant diff erences were found between the heterozygote and wild-type children in this study, heterozygotes had actually the lowest BMI, waist circumference, insulin concentration, and HOMA-IR index (23) . This is partially in accordance with our results. Since there were only 2 homozygous mutant subjects in our study, we were not able to diff erentiate between the effects of mutated hetero-and homozygotous state on phenotype.
Robitaille et al. showed no association of rs45487298: insA and rs12086634: T>G polymorphisms with MetS in French-Canadian men (24) . Variants were not associated with components of the MetS, except for higher plasma apolipoprotein B levels (24) . Several other studies found also no association of rs45487298: insA or rs12086634: T>G with metabolic characteristics (36-39).
As mentioned above, cohort of several hundreds of subjects, depending on variant allele frequency, would be required to detect moderate eff ect sizes of two analyzed HSD11B1 polymorphisms, and thousands of individuals would be needed to detect potentially small contributions of these variants to the complex phenotype of MetS. In general, many genetic association studies fail to replicate initial positive fi ndings (40) . Quality of these investigations depends on methodological issues related to phenotyping and genotyping, and issues related to the study design (40) . The key determinant of the quality and the most critical issue is the sample size (40, 41) . Beside this, the proper defi nition of phenotype/disease is essential for the quality of a genetic association study (40) . This is especially important for studies of MetS, since criteria for diagnosis were changing throughout the last decade and population of MetS patients represent very heterogeneous group.
The results of our preliminary study indicated a positive eff ect of rs45487298: insA variation on blood pressure and markers of insulin sensitivity in the control group. However, these positive fi ndings have to be replicated in a larger cohort of subjects. Several genetic association studies performed so far, yielded inconsistent results. The discrepancy might be also attributed to the ethnic and environmental diff erences between studied cohorts. Furthermore, other, yet unidentifi ed genetic variants in HSD11B1 gene or mutations in H6PD, the gene encoding the hexose-6-phosphate dehydrogenase (enzyme needed for 11β-HSD1 reductase activity), can also infl uence expression or activity of 11β-HSD1. Nonetheless, the role of 11β-HSD1 in insulin sensitivity and obesity seems to be complex and may be explained by its tissue-specifi c expression patterns.
In conclusion, this is the fi rst study performed in population from Bosnia and Herzegovina, in which a signifi cance of genetic variations of HSD11B1 gene was investigated in the pathogenesis of metabolic syndrome. We found a signifi cant association between rs45487298: insA, HSD11B1 gene polymorphism, and lower fasting plasma insulin and HOMA-IR index, as measures of insulin resistance in the control subjects. However, associations of this SNP with BMI and waist circumference, as markers of obesity, were not found. Future investigations including larger cohorts of subjects, as well as studies in other populations, are needed to substantiate these fi ndings.
